Drugs by condition
Drugs approved for stomach and esophageal cancer
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
52
Still marketed, NDA or BLA
Drug classes
17
Novel drugs
19
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for stomach and esophageal cancer.
- Oxderys (Doxorubicin Hydrochloride) · Avyxa Holdings Nov 9, 2026
- Favlyxa (Fluorouracil) · Avyxa Holdings Feb 20, 2026
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
- E-Z-Disk (Barium Sulfate) · Bracco Aug 1, 2025
- Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
All approved drugs for stomach and esophageal cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 275 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
HER2/neu Receptor Antagonist (6)
Azole Antifungal (4)
Programmed Death Receptor-1 Blocking Antibody (3)
Microtubule Inhibitor (3)
Endoglycosidase (2)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
Proton Pump Inhibitor (2)
Prostaglandin E1 Analog (2)
Bispecific HER2-directed Antibody (1)
- Ziihera Zanidatamab-Hrii · Jazz Pharms · 2024
Claudin 18.2-directed Cytolytic Antibody (1)
- Vyloy Zolbetuximab-Clzb · Astellas · 2024
Programmed Death Ligand-1 Blocker (1)
- Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017
Nucleoside Analog Antiviral (1)
- Lonsurf Tipiracil Hydrochloride, Trifluridine · Taiho Oncology · 2015
Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)
- Cyramza Ramucirumab · Eli Lilly and CO · 2014
CTLA-4-directed Blocking Antibody (1)
- Yervoy Ipilimumab · Bristol Myers Squibb · 2011
Echinocandin Antifungal (1)
- Eraxis Anidulafungin · Vicuron Holdings · 2006
Nucleoside Metabolic Inhibitor (1)
- Favlyxa Fluorouracil · Avyxa Holdings · 2026
Radiographic Contrast Agent (1)
- E-Z-Disk Barium Sulfate · Bracco · 2025
Class not listed in FDA's data (21)
- Enhertu Fam-Trastuzumab Deruxtecan-Nxki · Daiichi Sankyo · 2019
- Taxotere Docetaxel · Sanofi Aventis US · 1996
- Photofrin Porfimer Sodium · Pinnacle Biolgs · 1995
- Ethamolin Ethanolamine Oleate · Qol Medcl · 1988
- Oxderys Doxorubicin Hydrochloride · Avyxa Holdings · 2026
- Hercessi Trastuzumab-Strf · Accord Biopharma Inc. · 2024
- Micafungin In Sodium Chloride 0.9% Micafungin Sodium · Baxter Hlthcare Corp · 2023
- Docetaxel Docetaxel · Avyxa Holdings · 2022
- Konvomep Omeprazole, Sodium Bicarbonate · Azurity · 2022
- Glycopyrrolate Glycopyrrolate · Fresenius Kabi USA · 2022
- Glyrx-Pf Glycopyrrolate · Exela Pharma · 2018
- Caspofungin Acetate Caspofungin Acetate · Fresenius Kabi USA · 2016
- Docetaxel Docetaxel · Actavis · 2013
- Docetaxel Docetaxel · Sandoz · 2011
- Prilosec Omeprazole Magnesium · Azurity · 2008
- Nexium Esomeprazole Magnesium · Astrazeneca · 2008
- Nexium Esomeprazole Magnesium · Astrazeneca · 2006
- Nexium Esomeprazole Magnesium · Astrazeneca · 2001
- Doxorubicin Hydrochloride Doxorubicin Hydrochloride · Pfizer · 1987
- An-Sulfur Colloid Technetium Tc-99m Sulfur Colloid Kit · Sun Pharm Inds INC · 1978
- Robinul Glycopyrrolate · Hikma · 1975
Drugs in development for stomach and esophageal cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
6 discontinued brand-name drugs whose label still names it
- Cancidas Caspofungin Acetate
- Xeloda Capecitabine
- Famotidine Famotidine
- Esomeprazole Strontium Esomeprazole Strontium
- Docetaxel Docetaxel
- Zegerid Omeprazole, Sodium Bicarbonate
More on stomach and esophageal cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.